Literature DB >> 18520868

Comparisons among botulinum toxins: an evidence-based review.

Arnold W Klein1, Alastair Carruthers, Steven Fagien, Nicholas J Lowe.   

Abstract

BACKGROUND: Botulinum neurotoxin treatment is the most common aesthetic procedure in the United States. A number of serotypes and formulations are available worldwide. Similarities and differences among these toxins were evaluated by reviewing the existing literature.
METHODS: Reports of botulinum neurotoxin for aesthetic use, published in peer-reviewed literature or presented at recent professional congresses, were reviewed to summarize key features of different toxins. Data from therapeutic uses in comparable anatomical areas were included in the review when aesthetic literature was limited.
RESULTS: Serotypes of neurotoxins share molecular structures and mechanisms of action but exhibit important differences between serotypes and between different formulations within the same serotype, including differences in distribution/diffusion patterns and risk/benefit profiles. The differences attributable to dissimilarities in bacterial strains, manufacturing techniques, and assays are likely to influence clinical performance.
CONCLUSIONS: Injection patterns, techniques, dilutions diffusion, and injection volumes established for a specific formulation of botulinum neurotoxin are not likely to be applicable to other formulations, and formulations are not interchangeable by any single conversion ratio. A large proportion of the clinical literature documents the aesthetic uses of the Allergan formulation of botulinum toxin type A. Additional studies are needed to establish optimal procedures for the Ipsen formulation and botulinum neurotoxin, and for diverse aesthetic uses.

Mesh:

Substances:

Year:  2008        PMID: 18520868     DOI: 10.1097/PRS.0b013e318170813c

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  7 in total

1.  Duration of action of abobotulinumtoxina and onabotulinumtoxina: a randomized, double-blind study using a contralateral frontalis model.

Authors:  Mark S Nestor; Glynis R Ablon
Journal:  J Clin Aesthet Dermatol       Date:  2011-09

2.  [Treatment of crow's feet with two different botulinum toxin type A preparations in split-face technique].

Authors:  W Prager; E Wissmüller; B Kollhorst; A Böer; I Zschocke
Journal:  Hautarzt       Date:  2011-05       Impact factor: 0.751

Review 3.  Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction.

Authors:  Koenraad De Boulle; Steven Fagien; Boris Sommer; Richard Glogau
Journal:  Clin Interv Aging       Date:  2010-04-26       Impact factor: 4.458

4.  Botulinum toxin type-A in the treatment of glabellar lines.

Authors:  Leslie Winter; Jeffrey Spiegel
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-12-22

Review 5.  Safety and Patient Satisfaction of AbobotulinumtoxinA for Aesthetic Use: A Systematic Review.

Authors:  Joel L Cohen; Nicolo Scuderi
Journal:  Aesthet Surg J       Date:  2017-05-01       Impact factor: 4.283

6.  Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice.

Authors:  Welf Prager; Jürgen Huber-Vorländer; A Ziah Taufig; Matthias Imhof; Ulrich Kühne; Ruth Weissberg; Lars-Peter Kuhr; Volker Rippmann; Wolfgang G Philipp-Dormston; Thomas M Proebstle; Claudia Roth; Martina Kerscher; Claudius Ulmann; Tatjana Pavicic
Journal:  Clin Cosmet Investig Dermatol       Date:  2012-06-08

7.  OnabotulinumtoxinA Displays Greater Biological Activity Compared to IncobotulinumtoxinA, Demonstrating Non-Interchangeability in Both In Vitro and In Vivo Assays.

Authors:  David Rupp; Greg Nicholson; David Canty; Joanne Wang; Catherine Rhéaume; Linh Le; Lance E Steward; Mark Washburn; Birgitte P Jacky; Ron S Broide; Wolfgang G Philipp-Dormston; Mitchell F Brin; Amy Brideau-Andersen
Journal:  Toxins (Basel)       Date:  2020-06-13       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.